Compare Z & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | Z | RYTM |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.3B |
| IPO Year | 2014 | 2017 |
| Metric | Z | RYTM |
|---|---|---|
| Price | $28.97 | $114.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $38.67 | ★ $140.12 |
| AVG Volume (30 Days) | ★ 4.3M | 1.5M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.75 | 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,076,794,000.00 | N/A |
| Revenue This Year | $10.45 | $73.80 |
| Revenue Next Year | $8.87 | $73.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.19 | N/A |
| 52 Week Low | $26.67 | $74.50 |
| 52 Week High | $77.07 | $122.20 |
| Indicator | Z | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 67.54 |
| Support Level | $26.79 | $82.31 |
| Resistance Level | $34.53 | $119.75 |
| Average True Range (ATR) | 1.59 | 5.91 |
| MACD | -0.26 | 3.12 |
| Stochastic Oscillator | 9.56 | 98.14 |
Zillow Group Inc is a real estate technology company offering a digital platform that connects real estate customers with sellers, agents, loan officers, and other real estate-related professionals. With its tools and resources, Zillow helps real estate professionals grow their businesses, and for renters and housing providers, it offers a marketplace along with a set of end-to-end products and services to streamline applications, leases, payments, and more. The group operates various brands such as Zillow, Zillow Home Loans, Zillow Rentals, Zillow New Construction, Trulia, StreetEasy, Out East, HotPads, Follow Up Boss, ShowingTime, dotloop, and Zillow Closing. Its ecosystem spans the entire home journey from shopping to renting, buying, selling, and financing real estate.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.